Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7226436 | 0.87 | TSHR (0.47) | TSHRHPGD | |
| SCHEMBL6202791 | 0.82 | TSHR (0.58) | TSHRHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL10262574 | 0.76 | TSHR (0.47) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL21262205 | 0.73 | TSHR (0.45) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14410727 | 0.73 | TSHR (0.45) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1920902 | 0.73 | TSHR (0.45) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL10483634 | 0.72 | KMT2A (0.56) | TSHRHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL13484174 | 0.72 | HPGD (0.47) | TSHRHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL10341454 | 0.72 | KMT2A (0.49) | TSHRHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL21262203 | 0.72 | CHRM2 (0.46) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | UNIVERSITY COLLEGE DUBLIN (IE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | UNIVERSITY COLLEGE DUBLIN (IE) | 2021-01-28 | — | — | US | disclosed |
| US-20200216499-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216499-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216499-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | ACE, AGT, ACE2 | TSHR 2937/4885HPGD 455/4885ALDH1A1 621/4885 |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | TSHR 2536/4885HPGD 88/4885ALDH1A1 2545/4885 |
| US-20210024578-A1 | ANGIOTENSIN-(1-7) ANALOGS AND METHODS RELATING THERETO | ACE, AGT, ACE2 | TSHR 2937/4885HPGD 455/4885ALDH1A1 621/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | TSHR 1662/4885HPGD 85/4885ALDH1A1 2338/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | TSHR 1662/4885HPGD 85/4885ALDH1A1 2338/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | TSHR 1662/4885HPGD 85/4885ALDH1A1 2338/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | TSHR 1662/4885HPGD 85/4885ALDH1A1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.